What are adaptogens? Top blends for stress, focus and more
Reviews and recommendations are unbiased and products are independently selected. Postmedia may earn an affiliate commission from purchases made through links on this page.
Article content
For centuries, humans have turned to nature for healing, and one of the wise allies we can lean on is adaptogens — earthy, often bitter botanicals with balancing powers that help us adapt, recalibrate and rise above stress, both emotional and physical.
Article content
When we experience a stressful event, consuming adaptogens can help our bodies return to a state of balance known as homeostasis. These plants and herbs, such as ashwagandha, rhodiola rosea and schisandra are also believed to improve overall energy, vitality, athletic performance and strengthen the immune system.
Article content
Article content
This isn't new-age fluff. It's basic biology. It's the kind of ancient partnership that reminds us we're not machines that need fixing — we're ecosystems that, like nature, require tending.
Article content
All adaptogens help the body resist the effects of stress, but each offers unique support based on your specific needs.
Article content
Article content
For mental clarity, focus and energy: Lion's mane and chaga are top contenders — both are revered mushrooms rich in antioxidants and neuro-protective compounds. You'll often find them in instant coffee blends, coffee creamers or daily drink mixes.
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
3 hours ago
- Globe and Mail
Therapist Angela Jacobs Helps Patients Achieve Lasting Transformations and Healing
When clients need reflective counseling, Chiral Center Counseling PLLC is the ideal place to feel intensely seen and heard. Therapist Angela Jacobs specializes in trauma, eye movement desensitization and reprocessing (EMDR), relationship and narcissistic abuse, neurodivergence, and substance use for couples and individuals. Discover the difference that finding the right therapist makes at Chiral Center Counseling PLLC, where Angela Jacobs, LMHCA, helps clients feel heard, seen, and understood like never before. Jacobs helps clients get to the root of longstanding struggles, so they can heal and go on to move mountains, with professional support and guidance every step of the journey. Jacobs' unique approach to therapy makes her an ideal therapist for people looking to 'dig deep and get shit done.' Jacobs spent her early career as a successful entrepreneur, running an award-winning winery until her daughter was born. After leaving that industry, she returned to school for accounting, but was diagnosed with breast cancer shortly after graduating. During cancer treatment, she realized spending the rest of her life doing taxes would be far less rewarding than helping others build better lives in meaningful ways. Her immense store of varied life experience helps Jacobs provide exceptional care, empathy, and understanding to her clients. 'I am passionate about helping my clients find support, healing, and peace that will pay off in dividends of wellness far into the future,' Jacobs said. Patients receiving therapy from Jacobs at Chiral Center Counseling have praised her outstanding perspective, which she approaches from three angles: cognitive, emotional, and compassionate. Jacobs provides a nonjudgmental environment where clients receive careful yet firm assistance toward their goals. 'You may not know it, but grief, trauma, rejection, abandonment, and more could be holding you back from living your most fulfilling life,' Jacobs said. 'Let's process the hurt. You owe it to yourself to make time for your mental health.' Schedule a compatibility call today to learn whether Jacobs and Chiral Center Counseling offer the right setting for getting things done and making meaningful changes. The 15-minute compatibility call is free, and all session pricing is posted on the website. Jacobs offers equine-assisted therapy in Washington state near Chelan and Manson. She also provides numerous treatment options focused on depression, anxiety, substance use, impulsivity, ADHD and other neurodiversities, trauma and PTSD, grief, abandonment, attachment issues, and much more. Visit the Chiral Center Counseling website to learn more about psychotherapist Angela Jacobs or to schedule an appointment. Treatment is available for teens, adults, individuals, couples, and families to deal with a multitude of mental health conditions and emotional difficulties. Media Contact Company Name: Chiral Center Wellness PLL Contact Person: Angela Jacobs Email: Send Email Country: United States Website:
Globe and Mail
3 hours ago
- Globe and Mail
Bristol Myers Collaborates With BNTX for Oncology Candidate
BMY announced a strategic collaboration agreement with BioNTech BNTX. Both companies have entered into an agreement for the global co-development and co-commercialization of BioNTech's investigational bispecific antibody BNT327 across numerous solid tumor types. BNT327 is a novel investigational bispecific antibody combining two complementary, validated mechanisms in oncology into a single molecule. Shares of BNTX surged on the deal announcement. Shares of Bristol Myers lost 12.8% year to date compared with the industry 's decline of 2.2%. More on BMY & BNTX Agreement Per the terms, BMY and BNTX will jointly develop and commercialize BNT327, including the development of BNT327 as monotherapy and in combination with other products. Both BMY and BNTX own the right to develop BNT327 independently in further indications and combinations, including combinations of BNT327 with proprietary pipeline assets. Per the terms, BMY will make an upfront payment of $1.5 billion to BioNTech. In addition, BNTX will also receive $2 billion in non-contingent anniversary payments through 2028. BioNTech is also eligible to receive up to $7.6 billion in additional development, regulatory and commercial milestones. Both the companies will jointly share development and manufacturing costs along with profits on an equal basis. BNT327, a next-generation bispecific antibody candidate, targets PD-L1 and VEGF-A. It is currently being evaluated in multiple ongoing trials with more than 1,000 patients treated to date, including phase III studies with registrational potential evaluating BNT327 as first-line treatment in extensive stage small cell lung cancer (ES-SCLC) and non-small cell lung cancer (NSCLC). A phase III study evaluating the candidate in triple negative breast cancer (TNBC) is planned to start by the end of 2025. Data from ongoing trials (on a preliminary basis) underscore the potential for combining anti-PD-L1 and anti-VEGF-A – two well-established therapeutic targets – into a single molecule to deliver synergistic clinical benefits for patients across multiple tumor types. BMY Looks to Diversify Business BMY is depending on newer drugs like Opdualag, Reblozyl and Breyanzi to stabilize its revenue base as its legacy drugs face generic competition. BMY earlier won FDA approval for xanomeline and trospium chloride (formerly KarXT), an oral medication for the treatment of schizophrenia, in adults, under the brand name Cobenfy. The approval broadens BMY's portfolio. Cobenfy represents the first new pharmacological approach to treating schizophrenia in decades. This drug is expected to contribute meaningfully to BMY's top line in the coming years. BMY has experienced a few pipeline setbacks in recent months, which negatively impacted its share price. The late-stage ODYSSEY-HCM study evaluating cardiovascular drug Camzyos for the treatment of adult patients with symptomatic New York Heart Association (NYHA) class II-III non-obstructive hypertrophic cardiomyopathy did not meet its dual primary endpoints. The top-line results from the phase III ARISE study on schizophrenia drug Cobenfy were also disappointing. The study is evaluating the efficacy and safety of the drug as an adjunctive treatment to atypical antipsychotics in adults with inadequately controlled symptoms of schizophrenia. Developing bispecific antibodies that target two proteins, namely PD-1 and VEGF, has lately been one of the lucrative areas in cancer treatment. In November, Merck signed a deal with China-based LaNova Medicines for the latter's PD-1xVEGF targeting bispecific antibody candidate, LM-299. The latest entrant into this space is Pfizer PFE, which recently entered a multi-billion-dollar deal with Chinese biotech 3SBio for the latter's PD-1/VEGF bispecific antibody SSGJ-707. The deal is expected to be complete in third-quarter 2025. BMY's Zacks Rank & Stocks to Consider Bristol Myers currently carries a Zacks Rank #3 (Hold). A couple of better-ranked stocks in the pharma/biotech sector are Novartis NVS and Pfizer, both carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. The Zacks Consensus Estimate for Novartis' 2025 earnings per share (EPS) has risen from $8.47 to $8.74 over the past 60 days. EPS estimates for 2026 have jumped 20 cents to $9.02 during this timeframe. The stock has risen 18.6% so far this year. Pfizer's 2025 EPS estimate has risen from $2.97 to $3.06 in the past 60 days, while that for 2026 has gone up from $2.99 to $3.09 over the same timeframe. Zacks' Research Chief Names "Stock Most Likely to Double" Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest. This top pick is among the most innovative financial firms. With a fast-growing customer base (already 50+ million) and a diverse set of cutting edge solutions, this stock is poised for big gains. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months. Free: See Our Top Stock And 4 Runners Up Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Novartis AG (NVS): Free Stock Analysis Report Bristol Myers Squibb Company (BMY): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report BioNTech SE Sponsored ADR (BNTX): Free Stock Analysis Report
National Post
4 hours ago
- National Post
Donor Sibling Registry Celebrates 25 Years of Connecting Families
Article content Article content NEDERLAND, Colo. — The Donor Sibling Registry (DSR), the world's only global platform of its kind, connecting individuals conceived through sperm, egg, or embryo donation, proudly celebrates its 25th anniversary. The DSR has been instrumental in helping parents, donor-conceived people, donors, and their families find each other, fostering a global community built on connection, understanding, and shared genetic heritage. Article content Article content Founded in 2000 by Wendy Kramer and her son Ryan, the DSR was born from their journey to connect with Ryan's donor family. What began as a simple Yahoo message board has evolved into a powerful resource and global movement, facilitating almost 30,000 connections that have reshaped the lives of donor-conceived people and their families. The DSR, a 501(c)3 non-profit, has been at the forefront of advocacy, education, and research in the donor conception field. Article content Kramer explains, 'When we started the DSR, people had no idea they had the right to be curious, search for, find, and define their unique donor-family relationships.' The DSR's success is a testament to the growing desire for connection and information within the donor-conceived community. In an era of increasing genetic awareness, the DSR has become a vital platform for individuals seeking to understand their origins, explore their genetic connections, share medical information, and build relationships with their biological relatives. With almost 100,000 members, the DSR remains a trusted resource for families navigating the complex landscape of donor conception. Article content With DNA testing and direct-to-consumer genetic services becoming mainstream, the importance of ethical donor practices and open communication has never been more critical. With the evolution of reproductive technologies and a growing societal understanding of diverse family structures, the DSR remains committed to providing a safe and supportive space for connection, education, and advocacy. Article content 'We're incredibly proud of the work we've done over the past 25 years,' says co-founder Ryan Kramer. 'But our work is far from over. We'll continue to champion the rights of donor-conceived people, promote ethical practices within the fertility industry, and foster a world where everyone has access to their genetic ancestry, medical history, and close biological relatives.' Article content Article content Article content Article content Article content Article content
